RE: 48p Price Target27 Mar 2025 08:06
Update on AstraZeneca assay development projects
Both the developed assays (AR and DDR) have been approved for use by AstraZeneca and we are currently using the assays to test blood samples from patients. These developments put ANGLE in the position to be able to execute large scale clinical trials for AstraZeneca. In addition, ANGLE is working to progress discussions in other areas where we believe AstraZeneca could benefit from adopting CTC analysis.
ANGLE will now add the AR and DDR micronuclei assays to its menu of validated tests, which are available to pharma customers as a service from our clinical laboratory. Both the AR and DDR markets are considerable and growing, presenting an excellent opportunity for further pharma services contracts:
Β· The AR therapeutic market is estimated to reach US$9.2 billion in 2033, driven by the rising prevalence of prostate cancer, the growing adoption of targeted therapies, and the increasing demand for personalised medicine. There are over 46,000 patients in 181 AR clinical studies, with ANGLE targeting key players in the space.
Β· The DDR therapeutic market was estimated at US$8.2 billion in 2024 and is forecast to grow to US$30.3 billion over the next decade. The complex mechanisms involved in DNA repair and the potential for off-target effects necessitate rigorous preclinical and clinical evaluations. As such, real-time assessment of how the drug impacts the DDR pathway is particularly important during clinical trials and is only made possible through liquid biopsy. There are over 16,000 patients in 133 DDR clinical trials, again presenting a significant opportunity for ANGLE, with the addition of the DDR micronuclei assay complementing its Ξ³H2AX and pKAP1 DDR assays.
Sign In
Follow the stocks
